出典: meddic



  • Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
  • Young J1, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC; Swiss HIV Cohort Study.
  • Journal of acquired immune deficiency syndromes (1999).J Acquir Immune Defic Syndr.2015 Aug 1;69(4):413-21. doi: 10.1097/QAI.0000000000000662.
  • BACKGROUND: Patients with HIV exposed to the antiretroviral drug abacavir may have an increased risk of cardiovascular disease (CVD). There is concern that this association arises because of a channeling bias. Even if exposure is a risk, it is not clear how that risk changes as exposure cumulates.ME
  • PMID 25932884
  • Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
  • Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS.
  • HIV clinical trials.HIV Clin Trials.2015 Jul 2:1528433614Z0000000017. [Epub ahead of print]
  • PMID 26133089
  • Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
  • Bollen P1, Reiss P, Schapiro J, Burger D.
  • Expert opinion on drug safety.Expert Opin Drug Saf.2015 Jul 1:1-16. [Epub ahead of print]
  • INTRODUCTION: With the introduction of the coformulated dolutegravir, abacavir and lamivudine , a new single tablet regimen (STR) is made available for the use in treatment-naive and treatment-experienced HIV-infected patients. This drug combination is the fourth STR that will be positioned next to
  • PMID 26134478


  • Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis
  • HIV-1感染症におけるコンパニオン診断と利用のポイント (コンパ二オン診断の現状と展開 : 利用法のポイント)
  • 臨床病理 = The official journal of Japanese Society of Laboratory Medicine : 日本臨床検査医学会誌 63(11), 1323-1327, 2015-11
  • NAID 40020674873
  • Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia


Before taking abacavir, tell your doctor and pharmacist if you are allergic to any medications or any of the ingredients in abacavir tablets or solution. Ask your pharmacist for a list of the ingredients. tell your doctor and ...
Drug information on Abacavir for patients and consumers ... What is abacavir? Abacavir is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 3 ...


Description Abacavir.pngAbacavir Structural Formulae.pngDescyclopropyl Abacavirabacavir-300mgAbacavir.svgARMEDICLIN Ltda. Ariel Vergara

拡張検索abacavir succinate」「abacavir sulfate



PrepTutorEJDIC   license prepejdic

「〈U〉アルファベット / 〈U〉〈C〉《the ~》(物事の)初歩,入門,いろは《+『of』+『名』》」



硫酸アバカビル abacavir sulfate, ABC

abacavir succinate」


abacavirabacavir sulfate

abacavir sulfate」


abacavirabacavir succinate